News | Cath Lab | June 20, 2019

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium

Major cardiovascular conferences will collaborate on creating educational content for each other

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium

June 20, 2019 – VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter Cardiovascular Therapeutics (TCT) and the VEITHsymposium. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. VEITHsymposium is the leading global conference covering all aspects of vascular medicine, vascular surgery and endovascular intervention.

As part of this alliance, the two organizations will closely collaborate on creating educational content for physicians, surgeons and other healthcare professionals. The VEITHsymposium leadership will be actively involved in developing the endovascular program for TCT 2019, taking place Sept. 25-29 in San Francisco. The VEITHsymposium group will also plan dedicated critical limb ischemia and aortic sessions at TCT 2019. Similarly, CRF will actively participate in the development of a two-day hands-on training pavilion and other interventional sessions at this year’s VEITHsymposium, which will take place Nov. 19-23 in New York City.

“We are pleased to be partnering with such an esteemed educational conference as the VEITHsymposium,” said Juan F. Granada, M.D., president and CEO of CRF. “Over the last 45 years, they have had a remarkable influence on medical education and innovation in the field, which has had a tremendous impact on patient care.”

Watch the VIDEO: Cath Lab of the Future Cardiovascular Technologies to Watch, an interview with Granada at TCT 2017.

“This alliance between two leading continuing medical educational meetings has as its goal the provision of the best, most up-to-date information possible to all those specializing in the care of non-cardiac vascular disease patients,” said Frank J. Veith, chairman of VEITHsymposium.  “This unique alliance will lead to better, more appropriate care for the increasing number of vascular disease patients around the world, while recognizing the reality that many specialties are involved in providing this care.”

“Vascular disease is a leading cause of death and disability,” said Sahil A. Parikh, M.D., director, endovascular services at the Center for Interventional Vascular Therapy at New York-Presbyterian/ Columbia University Irving Medical Center and director of the endovascular program of TCT. “It’s critically important for physicians and other healthcare professionals to be educated and trained on the latest endovascular treatments. This alliance will help improve the survival and quality of life for patients with vascular disease by emphasizing multidisciplinary care of vascular patients.”

"Limitless opportunities for improved care of vascular patients is the primary goal of this new and exciting alliance between two well established giants in the area of education,” said Enrico Ascher, M.D., co-chairman of VEITHsymposium. “Providing a balanced, progressive environment where all vascular care professionals can learn from each other is one other motivating factor that led to this arrangement. I’m certain that this new concept of working together for the benefit of our patients and for the advancement of science will succeed big time!”

“For decades, TCT has been the foremost conference for cardiovascular interventional therapy and the VEITHsymposium has been the leading meeting for non-cardiac vascular medicine and surgery,” said Kenneth Ouriel, M.D., MBA, co-chairman of VEITHsymposium. “The new alliance provides the opportunity to expand non-cardiac vascular educational offerings at TCT and interventional cardiology opportunities at the VEITHsymposium. The end result will be the most comprehensive cardiovascular conference in the world today.”

For more information: www.crf.org, www.veithsymposium.org

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major